# An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old

> **NCT01724138** · PHASE4 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- β-thalassemia Major

## Interventions

- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT01724138
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-06
- **Primary completion:** 2014-04
- **Final completion:** 2014-10
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01724138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01724138, "An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01724138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*